Medicure gets FDA approval for Aggrastat HDB dosag
Jup, wenn nicht gerade was spezielles wie zb phase 2 oder 3 usw zu erwarten ist, dann gehe ich auch nicht von einem downer aus, sondern wohl eher von einem dicken anstieg.
Aktuell 2 $ Tipp im Bereich 0,28 CAD $ !
__________________________________________________
Sehr aussichtsreich erscheint auch die canadische V:ADL - ADIRA ENERGY LTD -
http://www.adiraenergy.com
Adira Energy, Ltd., is an energy company, conducts exploration of oil and gas offshore in the East Mediterranean. It is the operator of three petroleum exploration licenses offshore Israel; the Gabriella, Yitzhak & Samuel Licenses.
adira_energy.png (verkleinert auf 31%)
machen wir irgendwann auch ne pause oder sind die 3 CAD heute fällig ;)
Könnte es nicht nur ein kurzer Anstieg sein? Wenn man sich nämlich den 5-Jahres Chart anschaut, gab es schon mehrmals solche rasante Anstiege.
Gibt es also Gründe, warum es dieses mal nicht wieder zu einem Absturz kommen kann?
Ich bin noch investiert wenn auch nicht mehr ganz so voll wie am Anfang, aber ich denke das die Aktie die letzten Tage schon gut gerunnt ist und auch die nächsten Tage noch gut laufen wird, gerade wo im Biotechbereich in den USA gerade geknüppelt wird suchen die Investoren neue kleine Firmen (wie die hier).
Schätze zu dem Aktuellen Kurs einen Rücksetzer genauso hoch wie nochmal 50% höher....
Danke nochmal an Investox zu dieser guten Empfehlung :-)
Habe glaubs 2mal gekauf und einen ep von 0.30 :D
Gestern habe ich ein wenig zu früh etwa 1/3 verkauft, da ich noch was anderes kaufen wollte. Man ist ja nicht ewig liquide.
Weiss noch nicht wann ich den rest verkaufe. Der Einsatz ist jedefalls schon mehrfach draussen. Wer weiss plötzlich kommt doch noch die Übernahme und solange es aufwärts geht, wieso verkaufen.
Aber eben wenn ich so meine anderen Biotech Titel anschaue, hätte ich diese wohl besser früher verkauft und wäre nicht zu gierig geworden.
Dachte mir den ganzen Tag, gier frisst Hirn wenn man 600% vorne ist sollte das reichen .... glaube halt auch die Aktie ist jetzt heiß gelaufen die letzten Tage ohne News kehrt Katerstimmung ein bzw eine Anpassung des Kurses.
Nicht zu vergessen, aktuelle Marktkapitalisierung ist 36 Mil. CAD die müssen erstmal die nächsten Zahlen rechtfertigen. Selbst wenn Medicure 1 Million Gewinn macht im Jahr haben wir ein KGV von 36.
Die Übernahme wird nach dem Anstieg durch sein, bin ich fest überzeugt von.
Danke für dieses gute Investment :-) und allen Investierten weiterhin einen guten Lauf :-)
Was ich auch gerne mache und hier evt auch.
3 Teile
1/3 Einsatz raus
2/3 Halten zb zum Übernahme nicht verpassen
3/3 zum zocken...oben raus und unten wieder rein
Medicure Comments on Recent Trading Activity
2014-04-15 14:03 ET - News Release
WINNIPEG, MANITOBA -- (Marketwired) -- 04/15/14
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(OTCQB:MCUJF), a specialty pharmaceutical company, reports that, in view of the recent market activity in the Company's stock, the Investment Industry Regulatory Organization of Canada ("IIROC") has contacted the Company in accordance with its usual practice.
Although the Company ordinarily does not comment on market activity or market speculation, the Company is aware of the increased market activity in its common stock subsequent to our most recent press releases, including the announcement of March 26, 2014 relating to the financial results from the third quarter fiscal 2014 and the announcement of April 14, 2014 relating to the Company's advisory services agreement with Knight Therapeutics Inc.
Over the past several years the Company has been exploring opportunities to grow its business through acquisition. The Company is currently pursuing one specific opportunity, under which the Company would be a party to an acquisition. There is no assurance that this potential transaction, or any other transaction, is going to be completed.
The transaction contemplated is subject to, among other things, the negotiation and execution of a definitive binding agreements and other documentation, approval of the board of directors of the Company and that of the other parties to the transaction, and the completion of remaining due diligence activities. There can be no assurance that these conditions precedent, or any other conditions precedent, will be satisfied.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the development and commercialization of novel small molecule therapeutics. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.
To be added to Medicure's e-mail list, please visit: http://medicure.com/newsreleases.html.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, including the potential for any growth through acquisition, are based on the current assumptions, estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements.
Such risk factors include, among others, the Company's future product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended May 31, 2013.
Contacts:
Medicure Inc.
Dawson Reimer
President & COO
888-435-2220
204-488-9823 (FAX)
info@medicure.com
www.medicure.com
© 2014 Canjex Publishing Ltd. All rights reserved.